ArticleAnnals of surgical oncology2026
The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough over 95% of patients presenting with cutaneous squamous cell carcinoma (cSCC) are cured with surgery or radiotherapy, a subset develop locally advanced disease and undergo major resection and reconstruction. This may constitute high-risk surgery with potential for prolonged recovery and no assurance of oncological, functional, or aesthetic satisfaction. Immune checkpoint inhibitors have shown promise in this setting. We report a single-center UK experience with cemiplimab for locally advanced cSCC and our surgical experience of operating on a cemiplimab patient cohort.
methodsThis retrospective cohort study included all patients treated with cemiplimab for ≥ 3 months between November 2021 and May 2025. We report the objective response rate and describe operative findings and surgical outcomes for patients who progressed on treatment. We present our early experience and discuss patient selection.
resultsIn total, 25 consecutive patients were included, with a median follow-up of 16 months. The median age was 79 years (range 48-90). The objective response rate was 64%, comprising 11 complete and five partial responses. The median time to clinical response was 3 weeks. Among the 20 patients with operable disease, three (15%) underwent surgical resection for progressive disease with no surgical complications attributable to earlier cemiplimab. In total, 85% of patients avoided surgical intervention. Grade ≥ 3 toxicity occurred in 12% of patients, with one treatment discontinuation. DISCUSSION: Cemiplimab demonstrated robust activity in patients with advanced cSCC in this real-world population, with durable responses in long-term survivors. Salvage surgery appears feasible for patients with disease progression.
Indexed as
Identifiers
41855016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.